Martin Shkreli

Avoid buying the dip in IBM following its negative earnings pre-announcement, as it signals a broader contraction in corporate IT spending that could weigh on the entire tech sector. Consider a short position on Bristol Myers Squibb (BMY) due to a failing product pipeline and looming revenue cliffs for its core franchises. Take a bearish stance on Micron (MU) and the memory sector, as the IBM news suggests cyclical risks for hardware spending are being underestimated. For a high-conviction long opportunity, look to Alnylam (ALNY), which is currently viewed as significantly undervalued. Conversely, look for a contrarian entry point in Adobe (ADBE) on its recent weakness, as its fundamental business model remains stronger than enterprise peers like IBM.

Consider Q32 Bio (Q32) as a high-conviction long-term play following positive Phase II results for Benpigabart, a biologic for Alopecia Areata that lacks the "Black Box" safety warnings of current JAK inhibitors. With a registration-directed Phase III program slated for early 2027, the drug aims to capture a $5 billion market by offering a safer, more durable alternative to Olumiant and Litfulo. Conversely, maintain a bearish outlook on Agenus (AGEN), viewing recent price spikes as a "dead cat bounce" and targeting a return to the $3.00–$3.50 range. In the semiconductor space, exercise caution with Micron (MU) and Western Digital (WDC), as high capital expenditures and crowded positioning may limit near-term upside despite AI demand. Finally, remain skeptical of Bitcoin (BTC) and the broader memory trade, focusing instead on free cash flow over earnings per share to navigate current market volatility.

The semiconductor sector is currently experiencing a "crowded trade" sell-off, creating a potential value entry for SanDisk which is now down 50% from its peak. Investors should consider rotating capital out of hardware and into oversold software leaders like Adobe (ADBE), ServiceNow (NOW), and Workday (WDAY) as they show relative strength. In the biotech space, Acadia Pharmaceuticals (ACAD) represents a high-conviction long opportunity due to an undervalued Essential Tremor drug pipeline that could generate $5 billion in revenue. Prepare for significant market volatility in the next 12 months as major AI players OpenAI and Anthropic are predicted to launch their initial public offerings (IPOs). While SpaceX maintains an aggressive $800 price target, the most immediate actionable move is covering shorts on Western Digital (WDC) and Coreweave to lock in profits following recent dips.

Investors should monitor Vera Therapeutics (VERA) ahead of its imminent FDA decision date, as positive clinical markers in kidney disease treatment could potentially double or triple the stock price. For high-risk speculative growth, Shaz (SHAZ) offers significant upside if it secures a contract with Anthropic, though it remains a "follow the smart money" play based on major insider ownership. In the software sector, HubSpot (HUBS) and Adobe (ADBE) are high-conviction picks viewed as resilient against the "SaaS apocalypse" due to their deep integration and essential tools for professional creators. While NVIDIA (NVDA) and Micron (MU) face short-term sentiment headwinds, Bloom Energy (BE) and Terawolf (WOLF) are actionable ways to play the critical energy infrastructure needs of AI data centers. Conversely, caution is advised for Capricor Therapeutics (CAPR) ahead of its July 29th FDA panel and Broadcom (AVGO), which the analyst is currently shorting due to perceived contract losses.

Investors should consider Micron (MU) as a high-conviction "buy the dip" opportunity following its recent 7-10% sell-off, which is viewed as an overreaction to broader sector volatility. Meta Platforms (META) is a strong buy for enterprise expansion as it transitions into a cloud provider, a move that could generate $10–$20 billion in new high-margin revenue. Conversely, exercise extreme caution with NVIDIA (NVDA) and specialized cloud providers like Nebius, as Meta’s entry into the chip-rental market signals a potential peak in hardware demand. For aggressive traders, SELLAS Life Sciences (SLS) is a high-conviction short or avoid, as professional short-sellers are paying a massive 150% borrow rate betting on its failure. Long-term investors seeking a "moonshot" should look toward QCLS (QC Technologies) for its 5-year potential to disrupt the industry with photonic computing that scales far beyond current GPU limits.

Investors should look to Micron Technology (MU) as a top semiconductor play, with analysts setting price targets up to $200 driven by a structural shortage in high-bandwidth memory expected to last through 2027. In the biotech sector, Abivax (ABVX) remains a high-conviction long with potential to double or quadruple if it captures its projected $5 billion to $10 billion peak sales in the immunology market. Conversely, Cerebras (CBRS) and Sellas Life Sciences (SLS) are identified as high-risk short opportunities due to poor hardware margins and skepticism regarding clinical trial data integrity. NVIDIA (NVDA) continues to be a "buy on dips" as it aggressively reinvests to maintain hardware dominance over software-based AI competitors. For broader market timing, data suggests avoiding "day trading" and instead capturing "overnight" gains, as the majority of market returns occur between the daily close and the following open.

Investors should consider Micron Technology (MU) a high-conviction "buy the dip" opportunity, as memory remains a critical, undersupplied pillar of the AI infrastructure trade. In the biotech sector, Abivax (ABVX) is a strong long play due to "best-in-disease" efficacy for its Ulcerative Colitis drug, which positions the company as a potential $5 billion acquisition target for giants like Eli Lilly. Conversely, Sellas Life Sciences (SLS) is identified as a high-conviction short, with expectations that its upcoming clinical trial will fail completely because it cannot outperform modern standard-of-care results. Rocket Lab (RKLB) is also a short candidate, as its recent acquisition news is viewed as overhyped and its current valuation is unsustainable relative to its low-margin government contract business. Finally, for those with high risk tolerance, Evomune presents a contrarian buying opportunity following a stock crash, as the market is currently assigning zero value to its promising IL-18 drug pipeline.

Investors should consider a strategic rotation out of overextended semiconductor stocks and into recovering enterprise software leaders like ServiceNow (NOW), MongoDB (MDB), and Workday (WDAY). Within the chip sector, Micron (MU) offers a compelling valuation at 10x to 13x forward earnings, though investors should trade the momentum cautiously due to potential long-term supply risks from China. In the high-growth memory space, Samsung (SSNLF) and SK Hynix (000660.KS) remain dominant plays as HBM4 supply shortages are expected to persist through the AI infrastructure build-out. For high-conviction biotech opportunities, Biohaven (BHVN) is highlighted as a top pick ahead of potential FDA approvals, while Abivax (ABVX) is positioned as a long-term winner despite recent market controversy. Avoid Capricor Therapeutics (CAPR) and Omeros (OMER), as sentiment remains bearish due to historical underperformance and fundamental concerns.

Investors should capitalize on the current "Memory Trade" momentum through Micron Technology (MU), though they must remain vigilant for a cyclical peak and potential oversupply. BioCryst Pharmaceuticals (BCRX) represents a high-conviction value play with a price target of $28, driven by the long-term potential of its rare disease pipeline. Conversely, Intel (INTC) is a prime short candidate or pair-trade laggard due to its weak AI positioning and unimpressive revenue growth compared to competitors. Avoid Sharon AI entirely, as misleading claims regarding NVIDIA (NVDA) ownership serve as a significant red flag for potential fraud. For diversified exposure to the semiconductor supercycle, maintain positions in leaders like Broadcom (AVGO) and Applied Materials (AMAT) while seeking international alpha in Japanese plays like Kioxia.

Investors should consider a long position in Meta Platforms (META), as its massive distribution and AI leadership under Alex Wang make the stock appear undervalued. Roblox (RBLX) is identified as a high-conviction growth play with "double" potential due to 40% revenue growth, though investors must monitor high stock dilution. In the biotech sector, Spruce Biosciences (SPRB) is highlighted as a speculative opportunity with 10X potential for those with a high risk tolerance. Conversely, the semiconductor sector is viewed as a "bubble," making Intel (INTC) a primary short candidate and SanDisk a high-risk, small-sized short for experienced traders. Avoid long-term exposure to Novo Nordisk (NVO) due to looming patent expirations for Ozempic, and remain cautious of Google (GOOGL) as potential disappointment in its TPU hardware could trigger a reversal.

Investors should consider Cullinan Therapeutics (CGEM) as a value opportunity, as the stock currently trades around $15 despite sophisticated institutional investors recently paying $19 per share. In the semiconductor space, Micron (MU) and SK Hynix remain high-conviction plays driven by intense AI demand and strong sector momentum. While Amgen (AMGN) is an "execution machine" with massive revenue from Repatha and Crystexa, investors should remain cautious and monitor upcoming data for their weight loss drug, MariTide. Vaxcyte (PCVX) offers high-reward potential and could "certainly double" if its pneumococcal vaccine successfully competes with Pfizer, though it remains a high-risk biotech play. For long-term growth in the weight loss sector, keep a close eye on Viking Therapeutics (VKTX) and its lead candidate VK2735, though full commercialization is not expected until 2027.

Spruce Biosciences (SPRB) is a high-conviction "10x" opportunity with a personal price target of $500, driven by a potential $100 million Priority Review Voucher sale and a strategic BLA filing delay to Q4. Sarepta Therapeutics (SRPT) offers a strong value play with a "valuation floor," as its market cap sits near annual revenue and its gene therapy pipeline could reach $3B in sales. Investors should consider shorting IonQ (IONQ), which is described as a "house of cards" with inorganic revenue growth and a lack of essential quantum technology. Avoid Super Micro Computer (SMCI) due to high-risk smuggling allegations and Bristol Myers Squibb (BMY) as it faces a massive patent cliff for Eliquis and a heavy debt load. For long-term exposure to the successor of GPUs, look toward Optical Computing players like Lumentum (LITE), Coherent (COHR), and Fabrinet (FN).

NVIDIA (NVDA) is a primary investment opportunity as its growth is accelerating, with next-quarter revenue guidance of $78 billion massively beating expectations. The core thesis is to invest in the AI infrastructure theme, as the exponential demand for computing power represents a new industrial revolution. As a key semiconductor supplier, Micron (MU) is also positioned to benefit significantly from the sustained capital spending in the AI sector. Conversely, investors should avoid quantum computing company IonQ (IONQ) due to strong concerns about its revenue quality and fundamentals. For accredited investors, the bonds of private AI cloud provider Core Weave offer a high-yield opportunity, with its 2030 bonds yielding around 8%.

A high-conviction sell recommendation was issued for SELLAS Life Sciences (SLS), with the analyst stating the company's drug "does not work" and urging investors to exit the position immediately. Investors are advised to avoid quantum computing stocks like IonQ (IONQ) and D-Wave (QBTS) for AI applications, as the technology is considered a "dead end" for these workloads. A bearish sentiment was expressed for Viking Therapeutics (VKTX), with the analyst suggesting its positive run is likely over. Despite strong fundamentals, Eli Lilly (LLY) may have limited near-term upside from its $1,000 price, with valuation models suggesting a target of around $1,100. The key long-term theme is identifying the successor to NVIDIA (NVDA), with photonic computing seen as a more promising field than quantum.